Abbott Laboratories (ABT) Depreciation & Amortization (CF) (2009 - 2026)

Abbott Laboratories' Depreciation & Amortization (CF) history runs 18 years deep, the most recent figure standing at $381.0 million for Q1 2026.

• In Q1 2026, Depreciation & Amortization (CF) rose 13.39% year-over-year to $381.0 million; the TTM figure through Mar 2026 stood at $1.5 billion (up 10.13% YoY), while the FY2025 annual figure was $1.4 billion, up 7.01% from the prior year.
• Depreciation & Amortization (CF) came in at $381.0 million for Q1 2026 at Abbott Laboratories, up from $370.0 million in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $381.0 million in Q1 2026 to a low of $302.0 million in Q2 2023.
• A 5-year average of $334.5 million and a median of $332.0 million in 2023 frame the typical range for Depreciation & Amortization (CF).
• Across the five-year window, Depreciation & Amortization (CF) dropped 26.82% in 2022 and grew 13.39% in 2026, its largest moves.
• Abbott Laboratories' Depreciation & Amortization (CF) stood at $311.0 million in 2022, then climbed by 6.75% to $332.0 million in 2023, then gained by 3.01% to $342.0 million in 2024, then climbed by 8.19% to $370.0 million in 2025, then increased by 2.97% to $381.0 million in 2026.
• According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $381.0 million, $370.0 million, and $371.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison